Won, Bolling, Romano, Johnston, Ailawadi, Mehta, Baldridge, An, Kruse, Byrd, Green, & Malaisrie (2026). Long-Term Survival Advantage of Reoperative Surgical Mitral Valve Replacement Over Transcatheter Mitral Valve-in-Valve: A Multicenter Cohort.. The Annals of thoracic surgery.
Won, Bolling, Romano, Johnston, Ailawadi, Mehta, et al. Long-Term Survival Advantage of Reoperative Surgical Mitral Valve Replacement Over Transcatheter Mitral Valve-in-Valve: A Multicenter Cohort.. The Annals of thoracic surgery. 2026; PMID: 41995635
Won, Bolling, Romano, et al. Long-Term Survival Advantage of Reoperative Surgical Mitral Valve Replacement Over Transcatheter Mitral Valve-in-Valve: A Multicenter Cohort.[J]. The Annals of thoracic surgery. 2026.
@article{won2026,
author = {Won and Bolling and Romano and Johnston and Ailawadi and Mehta and Baldridge and An and Kruse and Byrd and Green and Malaisrie},
title = {Long-Term Survival Advantage of Reoperative Surgical Mitral Valve Replacement Over Transcatheter Mitral Valve-in-Valve: A Multicenter Cohort.},
journal = {The Annals of thoracic surgery},
year = {2026},
note = {PMID: 41995635},
}
TY - JOUR AU - Won AU - Bolling AU - Romano AU - Johnston AU - Ailawadi AU - Mehta AU - Baldridge AU - An AU - Kruse AU - Byrd AU - Green AU - Malaisrie TI - Long-Term Survival Advantage of Reoperative Surgical Mitral Valve Replacement Over Transcatheter Mitral Valve-in-Valve: A Multicenter Cohort. T2 - The Annals of thoracic surgery PY - 2026 AN - PMID:41995635 ER -
Although transcatheter mitral valve-in-valve replacement (mViV) is safe, long-term outcomes compared with reoperative surgical mitral valve replacement (rSMVR) remains unknown. This study compared long-term outcomes between mViV and rSMVR in patients with failing mitral bioprostheses.